Method of selectively inhibiting the activity of ACAT1 in the treatment of Alzheimer's disease
The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.
1. A method for decreasing the size and density of amyloid plaques comprising administering to a subject in need of treatment a microRNA that selectively inhibits the expression of Acyl-CoA:Cholesterol Acyltransferase 1 thereby decreasing the size and density of amyloid plaques in the subject, wherein the microRNA comprises SEQ ID NO. 41, 42, 43 or 44.
2. The method of claim 1 , wherein the microRNA is selectively delivered to the brain of the subject.
3. A method for decreasing cognitive decline associated with amyloid pathology comprising administering to a subject in need of treatment a microRNA that selectively inhibits the expression of Acyl-CoA:Cholesterol Acyltransferase 1 thereby decreasing cognitive decline associated with amyloid pathology in the subject, wherein the microRNA comprises SEQ ID NO. 41, 42, 43 or 44.
4. The method of claim 3 , wherein the microRNA is selectively delivered to the brain of the subject.
5. A method for treating Alzheimer's Disease comprising administering to a subject in need of treatment a microRNA that selectively inhibits the expression of Acyl-CoA:Cholesterol Acyltransferase 1 thereby treating the subject's Alzheimer's Disease, wherein the microRNA comprises SEQ ID NO. 41, 42, 43 or 44.
6. The method of claim 5 , wherein the microRNA is selectively delivered to the brain of the subject.